Wednesday, November 18, 2009 8:56:24 PM
There's 2 interesting scenarios. There's the catastrophic flat out denial of approval (HIGHLY unlikely). In that case 3 cents here we come.
Then, there's the possibility of a re-submit. In the short term this will cause mass panic and a sizable drop in share price since a whole heck of a lot of people will lose patience at that time and jump ship. Would probably be a correction into the 50-70 cent range in that case...which is around where the stock price was before Dean's last cc.
The interesting scenario above would be scenario 2, the re-submit. If that is the case, would we get another big run-up like we did now? If so, that would be a huge opportunity for some serious profits (well, at least for those who were wise enough to pull out a big chunk with the recent run-up).
And one last hypothetical is what if no FDA approval for months? As holders of NEPH can attest, the FDA certainly moves at a snail's pace. And to think a decision for IMGG is right around the corner may not be the case. The longer it takes the FDA, the lower the pps will go. That's just a disaster.
Hopefully the FDA will make a decision within the next 3 weeks. If not, it's going to get ugly.
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM